Ology Bioservices Named 2020 Company Of The Year By BioFlorida

BioFlorida distributes the award annually to a company that has “achieved significant milestones and has contributed to the growth of Florida’s life science industry.” BioFlorida is the voice of Florida’s life sciences industry, representing 6,700 establishments and research organizations in the BioPharma, MedTech, HealthIT & BioAg that collectively employ nearly 94,000 Floridians.

“We are honored to be named the 2020 BioFlorida Company of the Year,” said Peter H. Khoury, Ph.D., President and CEO of Ology Bio. “Our team at Ology Bio has been working diligently to serve our government and commercial clients in the development and manufacture of critical, life-saving drugs and biologics for the civilian and military population. As part of that work, we are very proud to be producing vaccines and monoclonal antibodies to eventually combat the spread of COVID-19, as well as supporting Operation Warp Speed.”

“We’re excited to recognize Ology Bioservices as the BioFlorida Company of the Year and celebrate their growth and efforts towards manufacturing vaccines, monoclonal antibodies, viruses and nucleic acids for the U.S. government and commercial clients,” said Nancy K. Bryan, President and CEO of BioFlorida. “With over 20 years of experience developing and manufacturing drugs and biologics for the U.S. government, companies like Ology Bioservices are poised to combat COVID-19 as well as other global health concerns.”

About Ology Bioservices Inc.

Ology Bio is a privately held, full-service Contract Development Manufacturing Organization (CDMO) serving both government and commercial clients, specializing in biologic drug substance manufacturing from early stage through commercial product. The company has 183,000 square feet of manufacturing, process development and QA/QC space in its state-of-the-art Advanced Development and Manufacturing Facility in Florida. The company’s infrastructure provides unique services to its clients, including full regulatory support from preclinical through licensure, clinical trial operational support and bioanalytical testing, as well as CGMP manufacturing up to Biosafety Level 3 (BSL3). Ology Bio has more than 20 years’ experience developing and manufacturing drugs and biologics for the U.S. government, with over $1.8 billion in government contracts awarded. The team at Ology Bio has decades of experience manufacturing, developing and licensing vaccines and protein/antibody therapeutics. For more information, visit the company’s website at www.ologybio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201030005630/en/